尊龙凯时人生就是搏·(中国区)官方网站

VOLUNTARY ANNOUNCEMENT - COMPLETION OF FIRST SUBJECT DOSING OF CLASS 1 INNOVATIVE DRUG TQB6411 (EGFR/c-MET BISPECIFIC ADC)

DISCLOSEABLE TRANSACTION - FULL ACQUISITION OF LANOVA MEDICINES

VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW INDICATION APPLICATION FOR MARKETING OF CULMERCICLIB CAPSULE FOR FIRST-LINE TREATMENT OF BREAST CANCER

VOLUNTARY ANNOUNCEMENT - "RECOMBINANT HUMAN COAGULATION FACTOR VIIA N01 FOR INJECTION" APPROVED FOR MARKETING

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 JUNE 2025

VOLUNTARY ANNOUNCEMENT - INDICATION OF ANLOTINIB HYDROCHLORIDE CAPSULES IN COMBINATION WITH CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF SOFT TISSUE SARCOMA APPROVED FOR MARKETING

VOLUNTARY ANNOUNCEMENT - NEW INDICATION OF LM-108 ("CCR8 MONOCLONAL ANTIBODY") INCLUDED IN BREAKTHROUGH THERAPY DESIGNATION PROCESS

VOLUNTARY ANNOUNCEMENT - PRECLINICAL AND CLINICAL DATA ON ROVADICITINIB PRESENTED AT EHA 2025